Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 5/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30402590 | 0.81 | KMT2A (0.49) | KMT2AL3MBTL1PDE4BRORCCTSL | |
| SCHEMBL22469507 | 0.81 | CTSK (0.40) | KMT2AL3MBTL1CTSKGAAKCNA3 | |
| SCHEMBL22469505 | 0.81 | CTSK (0.40) | KMT2AL3MBTL1CTSKGAAKCNA3 | |
| SCHEMBL25675300 | 0.79 | HTR2C (0.46) | KMT2AALDH1A1KDM1AHTR2C | |
| SCHEMBL25675134 | 0.78 | KMT2A (0.46) | KMT2AL3MBTL1PDE4BRORCCTSL | |
| SCHEMBL2821598 | 0.78 | PDE4B (0.54) | KMT2AL3MBTL1PDE4BRORCCTSL | |
| SCHEMBL13456796 | 0.76 | KMT2A (0.55) | KMT2AL3MBTL1PDE4BRORCCTSL | |
| SCHEMBL14428325 | 0.76 | KMT2A (0.55) | KMT2AL3MBTL1PDE4BRORCCTSL | |
| SCHEMBL23733555 | 0.76 | CTSK (0.40) | KMT2AL3MBTL1CTSKGAAKDM1A | |
| SCHEMBL19635977 | 0.75 | PDE4B (0.43) | KMT2AL3MBTL1PDE4BCTSLSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-119462659-A | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-113874079-B | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4122537-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3938047-B1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, NCAPD3 | KMT2A 2417/4885L3MBTL1 1553/4885PDE4B 3594/4885 |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | KMT2A 2126/4885L3MBTL1 1381/4885PDE4B 3573/4885 |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | KMT2A 2126/4885L3MBTL1 1381/4885PDE4B 3573/4885 |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | KMT2A 2126/4885L3MBTL1 1381/4885PDE4B 3573/4885 |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | KMT2A 2126/4885L3MBTL1 1381/4885PDE4B 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.